Description: Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. It also develops clinical pipeline products that include vaccines for grass, tree, and house dust mite, as well as a peanut allergy vaccine that is in pre-clinical stage. The company primarily sells its products in European countries. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.
Home Page: www.allergytherapeutics.com
Dominion Way
Worthing,
BN14 8SA
United Kingdom
Phone:
44 1903 844 700
Officers
| Name | Title |
|---|---|
| Mr. Manuel Llobet | CEO & Executive Director |
| Dr. Shaun Antony Furlong | CFO & Executive Director |
| Dr. Murray Skinner | Chief Scientific Officer |
| Ms. Sue Baker | Head of Human Resources |
| Simon Piggott | Head of Clinical Science |
| Alan Bullimore | Head of Communication & Market Development |
| Mr. Russell Picket | Group Financial Controller |
| Karley Charlotte Mouatt Cheesman | Company Secretary |
| Mr. Matthew Heath | Principal Scientist |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 52.3496 |
| Price-to-Sales TTM: | 6.9351 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |